%0 Journal Article
%A Arango, Celso
%A Baeza, Inmaculada
%A Bernardo, Miquel
%A Cañas, Fernando
%A de Dios, Consuelo
%A Díaz-Marsá, Marina
%A García-Portilla, María Paz
%A Gutiérrez-Rojas, Luis
%A Olivares, José Manuel
%A Rico-Villademoros, Fernando
%A Rodríguez-Jiménez, Roberto
%A Sánchez-Morla, Eva María
%A Segarra, Rafael
%A Crespo-Facorro, Benedicto
%T Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
%D 2018
%U http://hdl.handle.net/10668/12655
%X Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience.
%K Antipsicóticos
%K Antipsychotics
%K Depot
%K Drug utilization
%K Esquizofrenia
%K Inyectables de liberación prolongada
%K Long-acting injectable
%K Schizophrenia
%K Utilización de medicamentos
%~